Vanda Pharmaceuticals (VNDA) Enterprise Value (2009 - 2026)

Vanda Pharmaceuticals has disclosed Enterprise Value across 18 years of filings, most recently posting -$202.3 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$202.3 million, up 40.66% year-over-year; the trailing twelve-month figure through Mar 2026 was -$202.3 million (up 40.66% YoY), and the FY2025 annual result was -$263.8 million, up 29.57% from the prior year.
• Enterprise Value came in at -$202.3 million for Q1 2026 at Vanda Pharmaceuticals, up from -$263.8 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$202.3 million in Q1 2026 to a low of -$501.5 million in Q1 2023.
• The 5-year median for Enterprise Value is -$388.3 million (2023), against an average of -$389.7 million.
• Across the five-year window, Enterprise Value declined 15.24% in 2023 and jumped 40.66% in 2026, its largest moves.
• Vanda Pharmaceuticals' Enterprise Value stood at -$466.9 million in 2022, then climbed by 16.83% to -$388.3 million in 2023, then grew by 3.51% to -$374.6 million in 2024, then climbed by 29.57% to -$263.8 million in 2025, then grew by 23.32% to -$202.3 million in 2026.
• The last three Enterprise Value figures came in at -$202.3 million (Q1 2026), -$263.8 million (Q4 2025), and -$293.8 million (Q3 2025), per Business Quant data.